Market revenue in 2020 | USD 5,084.4 million |
Market revenue in 2028 | USD 8,800.3 million |
Growth rate | 7.1% (CAGR from 2020 to 2028) |
Largest segment | Mental health |
Fastest growing segment | Neurodegenerative Diseases |
Historical data | 2018 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer |
Key market players worldwide | Biogen Inc, Otsuka Pharmaceutical, Eli Lilly and Co, Merck & Co Inc, AstraZeneca PLC, Novartis AG ADR, Teva Pharmaceutical Industries Ltd, Johnson & Johnson, Pfizer Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to central nervous system therapeutic market will help companies and investors design strategic landscapes.
Mental health was the largest segment with a revenue share of 44.77% in 2020. Horizon Databook has segmented the UK central nervous system therapeutic market based on neurovascular diseases, cns trauma, mental health, neurodegenerative diseases, infectious diseases, cns cancer covering the revenue growth of each sub-segment from 2018 to 2028.
The rising prevalence of mental illnesses and increasing expenditure on mental health care by the UK government are the primary drivers of the UK CNS therapeutics market. Moreover, according to the Office for National Statistics, UK, dementia and Alzheimer’s disease are the leading causes of deaths in the country.
The main drugs used in the treatment of Alzheimer’s here are NMDA receptor antagonists and acetylcholinesterase inhibitors. Cholinesterase inhibitors are generically known as galantamine, donepezil, and rivastigmine, while NMDA receptor.
Parkinson’s disease is also expected to increase at a rapid pace over the forecast period, mainly due to aging population. For instance, the Parkinson’s disease Society of the United Kingdom reported that the prevalence of Parkinson’s disease in the UK .
Horizon Databook provides a detailed overview of country-level data and insights on the UK central nervous system therapeutic market , including forecasts for subscribers. This country databook contains high-level insights into UK central nervous system therapeutic market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account